Vinblastine sulfate adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Vinblastine sulfate
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Generic name
Class: Vinca alkaloid
Also reported as: Vinblastine Sulfate Injection

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Drug reports received through 30 Jun 2026. Device reports have a separate cutoff, 30 Sep 2026. Why a report count is not a rate.

Reports on file

From January 2004 to June 2026, FDA received 1,607 adverse event reports that name Vinblastine sulfate. In these reports the drug is a suspect or interacting product.

In the same period, 326 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 96 reports in the 12 months to June 2026 and 131 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 96 (under 0.1%) name Vinblastine sulfate. Reports from consumers or other non-health professionals were 4.8% of the reports that name Vinblastine sulfate and 45.8% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Vinblastine sulfate is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

The latest update of the FDA data, recorded on 28 Oct 2026, changed no count of this page.

In April to June 2026, FDA received 27 reports that name Vinblastine sulfate.
In January to March 2026, FDA received 11.
In April to June 2025, FDA received 23.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 181 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 1,602 of the 1,607 reports (99.7%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 181 terms.

Reaction terms in the reports that name Vinblastine sulfate, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 1,607 reports
Febrile neutropeniafever with low white blood cells	149	9.3%
Neutropenialow neutrophils, a type of white blood cell	129	8%
Pyrexiafever	99	6.2%
Nauseafeeling sick	67	4.2%
Pancytopenialow counts of all blood cells	66	4.1%
Neuropathy peripheralnerve damage in hands or feet	62	3.9%
Off label useused for a purpose or in a way not on the label	61	3.8%
Pulmonary toxicity	60	3.7%
Vomitingbeing sick	59	3.7%
Anaemialow red blood cells	54	3.4%
Neutrophil count decreased	53	3.3%
Sepsisa severe body-wide response to infection	53	3.3%
White blood cell count decreasedlow white cell count	47	2.9%
Dyspnoeashortness of breath	45	2.8%
Interstitial lung diseasescarring or inflammation of lung tissue	43	2.7%
Disease progressionthe disease advanced	41	2.6%
Abdominal painstomach or belly pain	39	2.4%
Diarrhoealoose or frequent stools	39	2.4%
Mucosal inflammation	31	1.9%
Hodgkin's disease	30	1.9%
Astheniaweakness or lack of energy	27	1.7%
Hypothyroidismunderactive thyroid	27	1.7%
Myelosuppression	27	1.7%
Constipation	26	1.6%
Acute myeloid leukaemia	25	1.6%
Hyponatraemialow blood sodium	25	1.6%
Product use in unapproved indicationused for a purpose not on the label	25	1.6%
Thrombocytopenialow platelets	25	1.6%
Pneumonialung infection	24	1.5%
Type 2 diabetes mellitustype 2 diabetes	24	1.5%
Fatiguetiredness	23	1.4%
Platelet count decreasedlow platelet count	23	1.4%
Dehydration	22	1.4%
Drug interactionan interaction between medicines	21	1.3%
Leukopenialow white blood cells	20	1.2%
Toxicity to various agentspoisoning or toxic effect of one or more substances	20	1.2%
Acute kidney injurysudden loss of kidney function	19	1.2%
Deaththe patient died; cause not stated by this term	18	1.1%
Septic shockshock arising from infection	17	1.1%
Hypotensionlow blood pressure	16	1%
Pneumonitis	16	1%
Pulmonary embolisma blood clot in the lung	16	1%
Azoospermia	15	0.9%
General physical health deteriorationgeneral decline in health	15	0.9%
Neurotoxicity	15	0.9%
Painpain, site not specified	15	0.9%
Chillschills or shivering	14	0.9%
Colitisinflamed bowel	14	0.9%
Testicular disorder	14	0.9%
Drug toxicity	13	0.8%

Download all 181 terms of Vinblastine sulfate (CSV)

The counts add to more than 1,607 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Vinblastine sulfate, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Congenital Anomaly/Birth Defect	Other Serious (Important Medical Events)	Not serious
2004	60	55	11	6	20	2	0	27	5
2005	34	28	7	3	13	0	0	13	6
2006	26	24	6	2	17	0	0	10	2
2007	47	46	8	0	18	0	0	33	1
2008	80	80	21	3	17	0	0	49	0
2009	22	22	2	2	9	2	0	14	0
2010	60	57	12	2	23	1	0	34	3
2011	149	147	22	8	41	3	0	102	2
2012	152	146	25	4	50	5	2	89	6
2013	21	19	2	1	10	0	0	8	2
2014	16	15	3	0	9	0	0	5	1
2015	25	22	7	2	12	1	0	7	3
2016	15	14	5	0	9	1	0	3	1
2017	14	13	3	0	11	0	0	4	1
2018	34	34	4	2	23	1	1	23	0
2019	88	86	6	5	36	3	0	68	2
2020	118	118	17	7	47	0	1	91	0
2021	102	101	16	6	46	2	0	82	1
2022	137	135	6	5	62	3	0	107	2
2023	112	111	8	24	35	6	1	79	1
2024	121	119	6	12	54	3	0	89	2
2025	121	119	4	9	52	0	2	81	2
2026	53	53	15	4	21	0	0	38	0

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Vinblastine sulfate, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Vinblastine sulfate, by the year in which FDA received them
Year	Reports
2004	52
2005	39
2006	28
2007	48
2008	78
2009	24
2010	60
2011	151
2012	158
2013	17
2014	15
2015	25
2016	15
2017	18
2018	41
2019	102
2020	117
2021	99
2022	134
2023	103
2024	135
2025	110
2026	38

Reports that name Vinblastine sulfate, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Vinblastine sulfate
Age	Reports	Share
Under 2	28	1.7%
2 to 11	62	3.9%
12 to 17	64	4%
18 to 44	392	24.4%
45 to 64	284	17.7%
65 to 74	201	12.5%
75 and over	139	8.6%
Age not given	437	27.2%

Sex of the patient in the reports that name Vinblastine sulfate
Sex	Reports	Share
Female	572	35.6%
Male	777	48.4%
Unknown or not given	258	16.1%

Type of reporter in the reports that name Vinblastine sulfate
Reporter	Reports	Share
Physician	680	42.3%
Pharmacist	107	6.7%
Other health professional	564	35.1%
Lawyer	1	0.1%
Consumer or non-health professional	77	4.8%
Not given	178	11.1%

Age and sex are as the report gives them. The reporter is the primary source in the report. 24.8% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Vinblastine sulfate record
Indication as recorded (MedDRA)	Reports	Share
Hodgkin's disease	494	30.7%
Hodgkin's disease	315	19.6%
Bladder cancer	27	1.7%
Optic glioma	24	1.5%
Langerhans' cell histiocytosis	22	1.4%
Diffuse large b-cell lymphoma	16	1%

The reporter fills in the indication, and the field is often empty. Each share is of all 1,607 reports.

Drugs in the same reports

Other drugs that the reports of Vinblastine sulfate name, in any role, in order of name
Drug	Reports that name the two
Adcetris	265
Bleomycin	278
Bleomycin sulfate	445
Cisplatin	215
Cyclophosphamide	209
Dacarbazine	1,062
Doxorubicin	236
Doxorubicin hydrochloride	961
Etoposide	180
Prednisone	162

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Vincristine sulfate same class
Vinorelbine same class
Vinblastine next in the A to Z list
Vincristin next in the A to Z list
Vimpat next in the A to Z list
Vincristine next in the A to Z list
Vimovo next in the A to Z list
Vincristine Hospira next in the A to Z list
Vimizim next in the A to Z list
Vildagliptin next in the A to Z list
Vincristine sulphate next in the A to Z list
Vilazodone next in the A to Z list

These links are for navigation. No count selected them. The class page lists each drug of the class.

Official pages

DailyMed labels for Vinblastine sulfateThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Vinblastine sulfate: adverse event reports that FDA received. https://reportedreactions.com/drug/vinblastine-sulfate/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Vinblastine sulfate as a suspect or interacting product. The 326 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Vinblastine sulfate was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Vinblastine sulfate?

No. It is a count of what people reported to FDA: 1,607 reports from January 2004 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Physician (42.3%), other health professional (35.1%) and pharmacist (6.7%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page